Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULFACETAMIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULFACETAMIDE SODIUM.
GANTRISIN vs SULFACETAMIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic